Pricing Log in Create free account

Inhibikase Therapeutics, Inc. (IKT) vs Sol-Gel Technologies Ltd. (SLGL)

Inhibikase Therapeutics, Inc. and Sol-Gel Technologies Ltd. are both Biotechnology companies. Inhibikase Therapeutics, Inc. and Sol-Gel Technologies Ltd. are of similar size ($209.3M and $199.8M). Inhibikase Therapeutics, Inc. grew revenue faster over the last twelve months: 110.9% against −92.5%. Inhibikase Therapeutics, Inc. has the higher net margin (0.00% vs −910.1%) and the higher return on invested capital (0.00% vs −6,630.2%). Across the 16 metrics below, Inhibikase Therapeutics, Inc. leads on 8 and Sol-Gel Technologies Ltd. on 8.

Valuation

Metric IKT SLGL Biotechnology median
P/E n/m n/m 10.60
P/S 1,005.21 111.18 9.40
P/B 1.71 4.15 2.13
Price to free cash flow n/m n/m 25.18
EV/EBITDA n/m n/m 0.66
EV/Sales 394.78 120.87 9.02
Earnings yield (28.67%) (9.24%) (32.88%)
Free cash flow yield (16.28%) (10.66%) (23.13%)

Profitability

Metric IKT SLGL Biotechnology median
Gross margin 100.00% 100.00% 68.51%
Operating margin 0.00% (986.96%) 0.00%
Net margin 0.00% (910.14%) 0.00%
Free cash flow margin 0.00% (1,185.18%) 0.00%
Return on equity (51.96%) (40.85%) (51.96%)
Return on assets (48.04%) (35.11%) (46.06%)
Return on invested capital 0.00% (6,630.24%) 0.00%

Growth

Metric IKT SLGL Biotechnology median
Revenue growth (TTM) 110.93% (92.50%) 6.76%
EPS growth (last fiscal year) 57.76% 42.37% 29.88%
Revenue growth, 5-year CAGR (42.21%) 17.19% 9.75%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric IKT SLGL Biotechnology median
Debt to equity 0.00 0.00 0.00
Current ratio 15.82 10.37 4.97
Net debt to EBITDA 3.44 3.23 1.01

Dividend

Metric IKT SLGL Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric IKT SLGL Biotechnology median
Market cap 209.30m 199.75m 161.82m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack